Building on the success of HPV and HBV vaccines, researchers are now developing innovative vaccine approaches targeting oncogenic drivers like KRAS, EGFR, and other early oncogenic neoantigens to intercept cancer before it emerges (156). Here, EGFR is linked to cancer.